Vutrisiran Sodium Patent Expiration
Vutrisiran Sodium is Used for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It was first introduced by Alnylam Pharmaceuticals Inc
Vutrisiran Sodium Patents
Given below is the list of patents protecting Vutrisiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Amvuttra | US10131907 | Glycoconjugates of RNA interference agents | Aug 24, 2028 | Alnylam Pharms Inc |
| Amvuttra | US10208307 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Jul 28, 2036 | Alnylam Pharms Inc |
| Amvuttra | US10570391 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | Nov 16, 2032 | Alnylam Pharms Inc |
| Amvuttra | US10612024 | Modified double-stranded RNA agents | Aug 14, 2035 | Alnylam Pharms Inc |
| Amvuttra | US10683501 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Jul 28, 2036 | Alnylam Pharms Inc |
| Amvuttra | US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Alnylam Pharms Inc |
| Amvuttra | US11286486 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | Jul 28, 2036 | Alnylam Pharms Inc |
| Amvuttra | US11401517 | Modified double-stranded RNA agents | Aug 14, 2035 | Alnylam Pharms Inc |
| Amvuttra | US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 12, 2029 | Alnylam Pharms Inc |
| Amvuttra | US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Alnylam Pharms Inc |
| Amvuttra | US9370581 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Alnylam Pharms Inc |
| Amvuttra | US9399775 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | Nov 16, 2032 | Alnylam Pharms Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳